Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of linezolid against multiple Nocardia species.

Literature DB >> 11257051

In vitro activities of linezolid against multiple Nocardia species.

B A Brown-Elliott¹, S C Ward, C J Crist, L B Mann, R W Wilson, R J Wallace.

Abstract

Linezolid was tested by broth microdilution against 140 clinical Nocardia isolates belonging to seven species. The MIC at which 50% of the strains are inhibited (MIC50) and MIC90 for all species other than Nocardia farcinica were 2 and 4 microg/ml. Linezolid is the first antimicrobial agent demonstrated to be active against all Nocardia species.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2001 PMID： 11257051 PMCID： PMC90460 DOI： 10.1128/AAC.45.4.1295-1297.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

1. Antimicrobial susceptibility patterns of Nocardia asteroides.

Authors: R J Wallace; L C Steele; G Sumter; J M Smith
Journal: Antimicrob Agents Chemother Date: 1988-12 Impact factor: 5.191

2. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.

Authors: T L Bowersock; S A Salmon; E S Portis; J F Prescott; D A Robison; C W Ford; J L Watts
Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191

3. Susceptibility testing of Nocardia species for the clinical laboratory.

Authors: R J Wallace; L C Steele
Journal: Diagn Microbiol Infect Dis Date: 1988-03 Impact factor: 2.803

4. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors: G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

5. Therapy of experimental cerebral nocardiosis with imipenem, amikacin, trimethoprim-sulfamethoxazole, and minocycline.

Authors: M E Gombert; T M Aulicino; L duBouchet; G E Silverman; W M Sheinbaum
Journal: Antimicrob Agents Chemother Date: 1986-08 Impact factor: 5.191

6. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia.

Authors: R J Wallace; E J Septimus; T W Williams; R H Conklin; T K Satterwhite; M B Bushby; D C Hollowell
Journal: Rev Infect Dis Date: 1982 Mar-Apr

7. Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica.

Authors: R J Wallace; M Tsukamura; B A Brown; J Brown; V A Steingrube; Y S Zhang; D R Nash
Journal: J Clin Microbiol Date: 1990-12 Impact factor: 5.948

8. Beta-lactam resistance in Nocardia brasiliensis is mediated by beta-lactamase and reversed in the presence of clavulanic acid.

Authors: R J Wallace; D R Nash; W K Johnson; L C Steele; V A Steingrube
Journal: J Infect Dis Date: 1987-12 Impact factor: 5.226

9. Results of therapy in systemic nocardiosis.

Authors: P J Geiseler; B R Andersen
Journal: Am J Med Sci Date: 1979 Nov-Dec Impact factor: 2.378

Review 10. Nocardial cerebral abscess cured with imipenem/amikacin and enucleation.

Authors: A Krone; K P Schaal; A Brawanski; B Schuknecht
Journal: Neurosurg Rev Date: 1989 Impact factor: 3.042

33 in total

1. Nocardia cyriacigeorgica septicemia.

Authors: Sameer Elsayed; Angela Kealey; Carla S Coffin; Ron Read; David Megran; Kunyan Zhang
Journal: J Clin Microbiol Date: 2006-01 Impact factor: 5.948

2. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.

Authors: Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jeng Teng; Po-Ren Hsueh
Journal: Antimicrob Agents Chemother Date: 2007-01-12 Impact factor: 5.191

Review 3. Update and actual trends on bacterial infections following liver transplantation.

Authors: Jose Luis del Pozo
Journal: World J Gastroenterol Date: 2008-08-28 Impact factor: 5.742

4. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy.

Authors: Federico Pea; Piergiorgio Cojutti; Alberto Pagotto; Francesco Cristini; Mario Furlanut; Pierluigi Viale
Journal: Antimicrob Agents Chemother Date: 2012-02-27 Impact factor: 5.191

5. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.

Authors: Chih-Cheng Lai; Wei-Lun Liu; Wen-Chien Ko; Yen-Hsu Chen; Hon-Ren Tan; Yu-Tsung Huang; Po-Ren Hsueh
Journal: Antimicrob Agents Chemother Date: 2011-02-22 Impact factor: 5.191

6. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.

Authors: Emilia Cercenado; Mercedes Marín; Mónica Sánchez-Martínez; Oscar Cuevas; José Martínez-Alarcón; Emilio Bouza
Journal: Antimicrob Agents Chemother Date: 2006-12-28 Impact factor: 5.191

7. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.

Authors: Barbara A Brown-Elliott; Christopher J Crist; Linda B Mann; Rebecca W Wilson; Richard J Wallace
Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191

Review 8. Newer antibacterial drugs for a new century.

Authors: Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal: Expert Opin Investig Drugs Date: 2010-02 Impact factor: 6.206

9. Secular trends of nocardia infection over 15 years in a tertiary care hospital.

Authors: R Matulionyte; P Rohner; I Uçkay; D Lew; J Garbino
Journal: J Clin Pathol Date: 2004-08 Impact factor: 3.411

10. A fatal case of Nocardia otitidiscaviarum pulmonary infection and brain abscess: taxonomic characterization by molecular techniques.

Authors: Ana Isabel Pelaez; Maria del Mar Garcia-Suarez; Angel Manteca; Ovidio Melon; Carlos Aranaz; Rafael Cimadevilla; Francisco Javier Mendez; Fernando Vazquez
Journal: Ann Clin Microbiol Antimicrob Date: 2009-04-14 Impact factor: 3.944